Cargando…

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?

SIMPLE SUMMARY: It is largely unknown how imatinib distributes within gastrointestinal stromal tumours (GISTs) and whether imatinib plasma concentrations correlate with tumour concentrations, whilst plasma concentrations are used to optimize treatment. In this exploratory study imatinib tumour conce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giraud, Eline L., de Jong, Loek A. W., van den Hombergh, Erik, Kaal, Suzanne E. J., van Erp, Nielka P., Desar, Ingrid M. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251911/ https://www.ncbi.nlm.nih.gov/pubmed/37296838 http://dx.doi.org/10.3390/cancers15112875

Ejemplares similares

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
por: van der Graaf, W. T. A., et al.
Publicado: (2018)

Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Relative Hypocalcaemia and Muscle Cramps in Patients Receiving Imatinib for Gastrointestinal Stromal Tumour
por: M. Zekri, Jamal, et al.
Publicado: (2006)

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
por: Kurokawa, Yukinori, et al.
Publicado: (2017)

Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
por: Hompland, Ivar, et al.
Publicado: (2016)

Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour
por: Bertucci, Alexandre, et al.
Publicado: (2019)

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours
por: Mu, Jianfeng, et al.
Publicado: (2020)

Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice
por: Macioszek, Szymon, et al.
Publicado: (2023)

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome
por: Akçakaya, P, et al.
Publicado: (2014)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?
por: IJzerman, N.S., et al.
Publicado: (2022)

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2018)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study
por: Tsukamoto, Shunsuke, et al.
Publicado: (2022)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
por: Pinder, Elizabeth M., et al.
Publicado: (2007)

Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Gastrointestinal Stromal Tumours: An Update
por: Somerhausen, Nicolas De Saint Aubain, et al.
Publicado: (1998)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry
por: IJzerman, Nikki S., et al.
Publicado: (2020)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
por: Wakai, T, et al.
Publicado: (2004)

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
por: Joensuu, H, et al.
Publicado: (2011)

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
por: Alassani, Fousséni, et al.
Publicado: (2019)

Gastrointestinal stromal tumour in Meckel's diverticulum
por: Chandramohan, K, et al.
Publicado: (2007)

The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)

Primary mesenteric gastrointestinal stromal tumour
por: Kirby, R., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fvj483ajsmfc33bakurgeata3v